Studies have also shown that JAML activation enhances TLR1/2 expression on tissue-resident CD8+ T cells (CD8+ TRMs), which suppresses tumor progression and prolongs survival in tumor-bearing mice. The gene discussed is CD8A; the disease is neoplasm.